When the results of the SELECT trial landed in the New England Journal of Medicine in November 2023, they confirmed what ...

Company embarks on a vision to make cardiovascular disease curable, preventable, and no longer the leading cause of death worldwide Led by founding CEO Tassos Gianakakos and fellow former MyoKardia ...

Cytokinetics, Incorporated CYTK announced that the FDA approved its lead pipeline candidate, aficamten, for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to ...

Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten. Aficamten is a next-in-class cardiac myosin ...

Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a ...

NewAmsterdam is singing data from its Broadway heart disease trial, hailing another phase 3 win for its cholesterol-busting candidate. Having struggled to wow investors with earlier data, the biotech ...

This story is the first in a series called "Ozempic: Weighing the Risks and Benefits." It was produced in part through a grant from the NIHCM Foundation. When the final results of the SELECT trial ...

An experimental Ventyx Biosciences drug led to statistically significant reductions in blood levels of a protein that’s an indicator of cardiovascular risk, preliminary Phase 2 results that support ...